Latest big drops, page 2
- AGIO Down 17.9% New
Agios falls 18% as FDA delays sickle cell decision over safety review
Agios fell about 18% after the FDA pushed its decision on mitapivat for sickle cell disease to Feb 1, 2027, while it weighs whether a safety program is needed.
- CACC Down 19.3% New
Credit Acceptance falls 19% as it cuts its loan cash-flow forecast
Credit Acceptance's adjusted earnings topped estimates, but it cut its forecast of loan net cash flows by $291 million, producing a loss under standard accounting.
- ILMN Down 18.6% UPDATED OCT 31New
Illumina falls 19% even as it raises its full-year forecast
Illumina shares fell after earnings despite a forecast raise. Tariff-related customer credits complicate the reported revenue miss.
- IOVA Down 35.4% New
Iovance falls 35% after lung cancer update highlights a small subgroup
Iovance called its lung cancer results positive, then the numbers showed most responses came from a small group of patients identified after the fact.
- NOW Down 27% New
ServiceNow falls 27% after forecasting slower contracted-revenue growth
ServiceNow beat its own targets, but forecast slower growth in contracted revenue after its stock had risen about 81% from its April 10 close.
- FTNT Down 20.1% New
Fortinet falls 20% after a beat as service growth slows
Fortinet beat forecasts and raised its revenue outlook, but cut its forecast for service revenue (subscriptions and support) while product sales did the heavy lifting.
- GOOGL Down 12.6% New
Alphabet falls 13% as cash burn and a profit miss overshadow a cloud boom
Alphabet fell about 13% on Thursday as investors weighed an ad-sales miss, negative free cash flow and a SpaceX paper loss against rapid Cloud growth.
- CSGP Down 14% New
CoStar falls 14% after a profit beat as net new bookings slump
CoStar beat profit forecasts and raised its outlook, but net new bookings fell by more than half and it agreed to pay about $730 million for Vexcel.
- UNF Down 10.4% New
UniFirst falls 10% on a report the FTC will sue to block the Cintas deal
UniFirst fell after Semafor reported the FTC plans to sue to block Cintas's $5.5 billion takeover, widening the gap between its share price and the offer.
- INOD Down 25.3% New
Innodata falls 25% amid reports of layoffs linked to a client ramp-down
Reports of Innodata layoffs tied to a smaller client project draw attention to its reliance on two customers that supplied 71% of Q2 revenue.
- ORIC Down 32% UPDATED OCT 31New
ORIC falls 32% after J&J shows early data for a rival prostate cancer drug
ORIC fell about 32% after J&J reported early prostate cancer results that Leerink described as a greater competitive threat to rinzimetostat.
-
Brazil's Ibovespa sinks 14% as Lula's surprise win reverses election bets
Investors had bet on a Flávio Bolsonaro win and tighter budgets. Lula's runoff victory sent Brazil's stocks, currency and bonds tumbling.
-
Rocket Lab falls 64% since May in a space-stock rout and a Neutron delay
Rocket Lab has lost about two-thirds of its value since May as space stocks slumped, it sold about $3 billion of new stock and Neutron slipped to 2027.
-
IG Group falls 50% since June after its Underdog deal and a forecast cut
IG Group's shares have halved since June after a $1.3 billion US prediction-market deal paused its buyback and weaker trading revenue led to a forecast cut.
-
Sea Limited falls 44% since August on spending worries and an AI cloud bet
Sea Limited has lost 44% since August as analysts flagged Shopee's spending and competition, and an Oct 20 memo unveiled an AI cloud plan with no budget.
- BE Down 11.2% New
Bloom Energy sinks 11% as record sales come with a cash burn
Bloom Energy beat forecasts and raised guidance, but its record quarter used $181 million of cash after a huge run, and the stock fell about 11%.
- CORT Down 20.1% New
Corcept falls 20% as a rival ovarian cancer drug aces its Phase 3 trial
Corcept had no news of its own. Genmab's Rina-S beat chemotherapy in the same ovarian cancer market as Corcept's new growth drug, Lifyorli.
- TNGX Down 16.4% UPDATED OCT 27New
Tango Therapeutics falls 16% after pancreatic cancer trial update
Tango's combination shrank tumors in 82% of 22 pancreatic cancer patients, but the stock fell 16% on a day its filing also disclosed job cuts and delays.
-
CATL falls 54% since June as taxes squeeze profit and customers move
CATL's Hong Kong shares have lost more than half their value since June as new battery taxes squeeze profit and carmakers shift orders to rivals.
- GEV Down 10.64% UPDATED NOV 3New
GE Vernova sinks 11% in an AI power selloff after Meta's spending scare
No GE Vernova announcement explained the move: it fell with other AI power stocks after Meta's results raised doubts about who pays for the AI build-out.